Induction of PD-L1 on monocytes: a new mechanism by which IVIg inhibits mixed lymphocyte reactions.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Immunobiology

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.imbio.2014.04.001PMID 24875729
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• IVIg prevents the in vitro activation of T cells by neutralizing the T cell activators.

  2013cited by this paper
• Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.

  2013cited by this paper
• The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease

  2013influential reference
• Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

  2013cited by this paper
• References Subscriptions Permissions Email Alerts PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection

  2013cited by this paper
• Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc− mouse model

  2012cited by this paper
• Immunology mini-review: the basics of T(H)17 and interleukin-6 in transplantation.

  2012cited by this paper
• Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation.

  2012cited by this paper
• Belatacept in kidney transplantation

  2012cited by this paper
• IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.

  2012cited by this paper
• Immune tolerance and transplantation.

  2012cited by this paper
• Press Review

  2011cited by this paper
• Exosome Secretion: Molecular Mechanisms and Roles in Immune Responses

  2011cited by this paper
• TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition

  2011cited by this paper
• Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?

  2011cited by this paper
• IL-6 Promotes Cardiac Graft Rejection Mediated by CD4+ Cells

  2011cited by this paper
• Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients

  2011cited by this paper
• Key aspects for successful immunoglobulin therapy of primary immunodeficiencies

  2011cited by this paper
• Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation.

  2010cited by this paper
• Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease.

  2010influential reference
• Inflammatory cytokines as a third signal for T cell activation.

  2010cited by this paper
• The effects of IL-6 on CD4 T cell responses.

  2009cited by this paper
• T cell activation.

  2009cited by this paper
• PD‐1/PD‐L1, PD‐1/PD‐L2, and other co‐inhibitory signaling pathways in transplantation

  2008cited by this paper
• Interferon Gamma Enhances Clonal Expansion and Survival of CD4+ T Cells

  2008cited by this paper
• PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection1

  2007cited by this paper
• Tissue expression of PD-L1 mediates peripheral T cell tolerance

  2006cited by this paper
• High dose intravenous immunoglobulin treatment: Mechanisms of action

  2005cited by this paper
• Acute graft-versus-host disease: from the bench to the bedside.

  2005cited by this paper
• Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo1

  2005cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Membranes as messengers in T cell adhesion signaling

  2004cited by this paper
• Pooled Human Gammaglobulin Modulates Surface Molecule Expression and Induces Apoptosis in Human B Cells

  2003cited by this paper
• Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1

  2003cited by this paper
• Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.

  2002cited by this paper
• Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation.

  2002cited by this paper
• The role of CTLA‐4 in induction and maintenance of peripheral T cell tolerance

  2002cited by this paper
• Pathways of allorecognition: implications for transplantation tolerance.

  2002cited by this paper
• Combination therapy with tacrolimus and anti‐thymocyte globulin for the treatment of steroid‐resistant acute graft‐versus‐host disease developing during cyclosporine prophylaxis

  2001cited by this paper
• Chronic graft-versus-host disease: clinical manifestation and therapy

  2001cited by this paper
• Donor IFN-γ Receptors Are Critical for Acute CD4+ T Cell-Mediated Cardiac Allograft Rejection1

  2001cited by this paper
• A RANDOMIZED AND PROSPECTIVE STUDY COMPARING TREATMENT WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN WITH MONOCLONAL ANTIBODIES FOR RESCUE OF KIDNEY GRAFTS WITH STEROID-RESISTANT REJECTION

  2001cited by this paper
• ICOS co-stimulatory receptor is essential for T-cell activation and function

  2001cited by this paper
• Donor IFN-gamma receptors are critical for acute CD4(+) T cell-mediated cardiac allograft rejection.

  2001cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression1

  2000cited by this paper
• CD40‐CD40 ligand

  2000cited by this paper
• The impact of immunosuppressive drugs on the analysis of T cell activation.

  2000cited by this paper
• Three-dimensional segregation of supramolecular activation clusters in T cells

  1998cited by this paper
• Down‐Regulation of Lymphokine Synthesis by Intravenous Gammaglobulin is Dependent Upon Accessory Cells

  1998cited by this paper
• Interleukin-1 receptor antagonist: role in biology.

  1998cited by this paper
• Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation.

  1996cited by this paper
• Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft‐versus‐host disease

  1996cited by this paper
• Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins.

  1996cited by this paper
• Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.

  1996influential reference
• T-cell activation

  1995influential reference
• Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.

  1994cited by this paper
• Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin.

  1994cited by this paper
• Immune Modulatory Effects of Immunoglobulins on Cell‐Mediated Immune Responses In Vitro

  1993influential reference
• Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.

  1990influential reference
• Evidence for immunosuppression by high-dose gammaglobulin.

  1987cited by this paper
• Nephro-urology Monthly Nephro-urology Monthly Nephro-urology Monthly Kowsar Efficacy of Anti-interleukin-2 Receptor Antibody (daclizumab) in Re- Ducing the Incidence of Acute Rejection after Renal Transplantation Implication for Health Policy/practice/research/medical Education

  year unknowncited by this paper

• Potential of Circulating Immune Cells as Biomarkers of Nivolumab Treatment Efficacy for Advanced Hepatocellular Carcinoma.

  2021cites this paper
• Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia

  2021cites this paper
• Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin

  2016cites this paper
• NLRP10 A Potential Contributor to the Anti-Inflammatory Effects of IVIg in Sepsis

  2016cites this paper
• Use of IVIg to identify potential miRNA targets for allograft rejection and GvHD therapy

  2015cites this paper
• Immunorégulation de la réaction du greffon contre l'hôte (GvHD) dans un modèle murin xénogénique : le rôle des immunoglobulines intraveineuses (IVIG)

  2015cites this paper